Assessment of the 24th week success of anti-retroviral therapy in ACTHIV-IST Database: Results from a region with increasing incidence.

Assessment of the 24th week success of anti-retroviral therapy in ACTHIV-IST Database: Results from a region with increasing incidence. Jpn J Infect Dis. 2019 Jan 31;: Authors: Bolukcu S, Mete B, Gunduz A, Karaosmanoglu HK, Sargin F, Durdu B, Aydin OA, Yildiz D, Dokmetas I, Aslan T, Tabak F Abstract We aimed to assess 24-week virological and immunological success of treatment naive and experienced patients included in ACTHIV-IST database. ACTHIV-IST database were screened retrospectively from January 2012 to January 2014. Data of these patients such as age, sex, being treatment naive or experienced, date of diagnosis, date of commencing antiretroviral therapy, antiretroviral therapy regimen, CD4+ cell count and viral load before and after therapy were analyzed. In the 24th week of antiretroviral therapy, virological and immunological failures were 40 (17.9%) and 29 (14.1%), respectively. Virological failure was associated with a baseline viral load > 100,000 copies (p=0.004). CD4+ cell count lower than 200 cells/µl was not found to be associated with virological failure (p=0.843). Immunological failure was substantially rare in patients with a baseline CD4+ cell count >200 cells/µl (p=0.005). While an HIV-RNA ≤100,000 copies/ml was protective against virological failure in the 24th week, in individuals having an HIV-RNA >100,000 copies/ml virological failure was 3.2 times more likely to occur. Baseline virological failur...
Source: Japanese Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Jpn J Infect Dis Source Type: research